Creutzfeldt-Jakob Disease (CJD) Market Research Report, by type (Sporadic CJD, Hereditary CJD), diagnosis (imaging, brain biopsy), treatment (opiate drugs, clonazepam, sodium valproate), end users (hospitals, clinics) - global forecast till 2027
ID: MRFR/Pharma/4419-HCR | August 2022 | Region: Global | 100 Pages
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Creutzfeldt-Jakob Disease (CJD) Market, by Type
6.1 Introduction
6.2 Sporadic CJD
Market Estimates & Forecast, 2020 – 2027
6.3 Hereditary CJD
Market Estimates & Forecast, 2020 – 2027
6.4 Acquired CJD
Market Estimates & Forecast, 2020 – 2027
Chapter 7. Global Creutzfeldt-Jakob Disease (CJD) Market, by Diagnosis
7.1 Introduction
7.2 By Imaging
Market Estimates & Forecast, 2020 – 2027
7.2.1 Electroencephalogram (EEG)
7.2.2 Magnetic Resonance Imaging (MRI)
7.2.3 Computerized Tomography (CT)
7.2.4 Others
7.3 Spinal Fluid Tests
Market Estimates & Forecast, 2020 – 2027
7.4 Brain Biopsy
Market Estimates & Forecast, 2020 – 2027
7.5 Others
Chapter 8. Global Creutzfeldt-Jakob Disease (CJD) Market, by Treatment
8.1 Introduction
8.2 Opiate Drugs
Market Estimates & Forecast, 2020 – 2027
8.3 Clonazepam
Market Estimates & Forecast, 2020 – 2027
8.4 Sodium valproate
Market Estimates & Forecast, 2020 – 2027
8.5 Others
Chapter 9. Global Creutzfeldt-Jakob Disease (CJD) Market, by End User
9.1 Introduction
9.2 Hospitals and Clinics
Market Estimates & Forecast, 2020 – 2027
9.3 Research Organizations
Market Estimates & Forecast, 2020 – 2027
9.4 Diagnostic Centers
Market Estimates & Forecast, 2020 – 2027
9.5 Medical Research Institutes
Market Estimates & Forecast, 2020 – 2027
9.6 Others
Chapter 10. Global Creutzfeldt-Jakob Disease (CJD) Market, by Region
10.1 Introduction
10.2 America
10.2.1 North America
10.2.1.1 U.S.
10.2.1.2 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 Italy
10.3.1.4 Spain
10.3.1.5 U.K
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
Chapter 11. Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
Chapter 12 Company Profiles
12.1 Teva Pharmaceutical Industries Ltd.
12.1.1 Company Overview
12.1.2 Type Overview
12.1.3 Financials
12.2.4 Key Developments
12.1.5 SWOT Analysis
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Company Overview
12.2.2 Type Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 Mylan N.V.
12.3.1 Company Overview
12.3.2 Type Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.3.5 SWOT Analysis
12.4 Sandoz International GmbH
12.4.1 Company Overview
12.4.2 Type/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.4.5 SWOT Analysis
12.5 Sun Pharmaceutical Industries Ltd.
12.5.1 Company Overview
12.5.2 Type Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Apotex Inc.
12.6.1 Company Overview
12.6.2 Type Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Par Pharmaceutical.
12.7.1 Overview
12.7.2 Type Overview
12.7.3 Financials
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 GENERAL ELECTRIC
12.8.1 Overview
12.8.2 Type Overview
12.8.3 Financials
12.8.4 Key Developments
12.8.5 SWOT Analysis
12.9 Koninklijke Philips N.V.
12.9.1 Overview
12.9.2 Type Overview
12.9.3 Financials
12.9.4 Key Developments
12.9.5 SWOT Analysis
12.10 Medtronic
12.10.1 Overview
12.10.2 Type Overview
12.10.3 Financials
12.10.4 Key Developments
12.10.5 SWOT Analysis
12.11 Siemens AG
12.11.1 Overview
12.11.2 Type Overview
12.11.3 Financials
12.11.4 Key Developments
12.11.5 SWOT Analysis
12.12 Accuray Incorporated
12.12.1 Overview
12.12.2 Type Overview
12.12.3 Financials
12.12.4 Key Developments
12.12.5 SWOT Analysis
12.13 Others
Chapter 13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of global Creutzfeldt-Jakob disease (CJD) market
Chapter 14 Appendix
LIST OF TABLES
Table 1 Creutzfeldt-Jakob Disease (CJD) Market Industry Synopsis, 2020 – 2027
Table 2 Global Creutzfeldt-Jakob Disease (CJD) Market Estimates and Forecast, 2020 – 2027, (USD Million)
Table 3 Global Creutzfeldt-Jakob Disease (CJD) Market by Region, 2020 – 2027, (USD Million)
Table 4 Global Creutzfeldt-Jakob Disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 5 Global Creutzfeldt-Jakob Disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 6 Global Creutzfeldt-Jakob Disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 7 Global Creutzfeldt-Jakob Disease (CJD) Market by End User, 2020 – 2027, (USD Million
Table 8 North America Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 9 North America Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 10 North America Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 11 North America Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 12 U.S. Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 13 U.S. Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 14 U.S. Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 15 U.S. Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 16 Canada Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 17 Canada Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 18 Canada Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 19 Canada Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 20 South America Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 21 South America Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 22 South America Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 23 South America Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 24 Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 25 Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 26 Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 27 Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 28 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 29 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 30 Western Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 31 Western Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 32 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 33 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 34 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 35 Eastern Europe Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 36 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 37 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 38 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 39 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
Table 40 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Type, 2020 – 2027, (USD Million)
Table 41 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Diagnosis, 2020 – 2027, (USD Million)
Table 42 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by Treatment, 2020 – 2027, (USD Million)
Table 43 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market by End User, 2020 – 2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Creutzfeldt-Jakob Disease (CJD) Market
Figure 3 Market Dynamics for Global Creutzfeldt-Jakob Disease (CJD) Market
Figure 4 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Type 2020
Figure 5 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Diagnosis 2020
Figure 6 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Treatment, 2020
Figure 7 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by End User, 2020
Figure 8 Global Creutzfeldt-Jakob Disease (CJD) Market Share, by Region, 2020
Figure 9 North America Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020
Figure 10 Europe Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020
Figure 11 Asia Pacific Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020
Figure 12 The Middle East & Africa Creutzfeldt-Jakob disease (CJD) Market Share, by Country, 2020
Figure 13 Global Creutzfeldt-Jakob Disease (CJD) Market: Company Share Analysis, 2020 (%)
Figure 14 Teva Pharmaceutical Industries Ltd.: Key Financials
Figure 15 Teva Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 16 Teva Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 17 F. Hoffmann-La Roche Ltd: Key Financials
Figure 18 F. Hoffmann-La Roche Ltd: Segmental Revenue
Figure 19 F. Hoffmann-La Roche Ltd: Geographical Revenue
Figure 20 Mylan N.V. : Key Financials
Figure 21 Mylan N.V. : Segmental Revenue
Figure 22 Mylan N.V. : Geographical Revenue
Figure 23 Sandoz International GmbH: Key Financials
Figure 24 Sandoz International GmbH: Segmental Revenue
Figure 25 Sandoz International GmbH: Geographical Revenue
Figure 26 Sun Pharmaceutical Industries Ltd.: Key Financials
Figure 27 Sun Pharmaceutical Industries Ltd.: Segmental Revenue
Figure 28 Sun Pharmaceutical Industries Ltd.: Geographical Revenue
Figure 29 Apotex Inc.: Key Financials
Figure 30 Apotex Inc.: Segmental Revenue
Figure 31 Apotex Inc.: Geographical Revenue
Figure 32 Par Pharmaceutical.: Key Financials
Figure 33 Par Pharmaceutical.: Segmental Revenue
Figure 34 Par Pharmaceutical.: Geographical Revenue
Figure 35 GENERAL ELECTRIC: Key Financials
Figure 36 GENERAL ELECTRIC: Segmental Revenue
Figure 37 GENERAL ELECTRIC: Geographical Revenue
Figure 38 Koninklijke Philips N.V.: Key Financials
Figure 39 Koninklijke Philips N.V.: Segmental Revenue
Figure 40 Koninklijke Philips N.V.: Geographical Revenue
Figure 41 Medtronic: Key Financials
Figure 42 Medtronic: Segmental Revenue
Figure 43 Medtronic: Geographical Revenue
Figure 44 Siemens AG: Key Financials
Figure 45 Siemens AG: Segmental Revenue
Figure 46 Siemens AG: Geographical Revenue
Figure 47 Accuray Incorporated: Key Financials
Figure 48 Accuray Incorporated: Segmental Revenue
Figure 49 Accuray Incorporated: Geographical Revenue
Speak to Analyst
Request a Free Sample
Creutzfeldt-Jakob disease (CJD) market Scenario:
Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death. The early stage symptoms of the disease include failing memory and lack of coordination followed by visual disturbances. As the disease progresses, mental deterioration becomes prominent leading to weakness of extremities, and conditions like coma. The CJD disease can be classified into three major groups, namely sporadic CJD, hereditary CJD, and acquired CJD. Sporadic CJD is the most common form of the disease and accounts for approximately 85% of the total reported cases. A majority of the treatments available in the market are symptomatic and aimed at alleviating pain. The risk factors for the development of the disease are inclusive of old age, familial CJD genetics, and others. Increasing prevalence of Creutzfeldt-Jakob disease and growing geriatric population are estimated to be the major drivers for the market growth during the forecast period. In 2017, the National Institute of Neurological Disorders and Stroke stated that approximately 300 new cases of CJD are reported every year within the U.S. Moreover, it has been estimated that the symptomatic onset of the medical condition occurs predominantly around the age of 60. Additionally, according to the United States Census Bureau, the global geriatric population is projected to more than double and reach 1.6 billion from 2025 to 2050. Additionally, factors such as increasing per capita healthcare expenditure and extensive research and development by the market players will drive the market growth. However, lack of awareness, limited availability of therapeutics, and erroneous diagnostic results are estimated to restrain the Creutzfeldt-Jakob disease (CJD) market growth during the forecast period.
The Creutzfeldt-Jakob disease (CJD) market is expected to grow at an approximate CAGR of 17.5% during forecast period.
Intended Audience
- Pharmaceutical companies
- Biotechnological institutes
- Government and Private Laboratories
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Market Research and Consulting Service Providers
Figure 1- Creutzfeldt-Jakob Disease (CJD) Market Share, by Region
Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation
Segmentation
The Creutzfeldt-Jakob disease (CJD) market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is segmented into sporadic CJD, hereditary CJD, and acquired CJD. On the basis of the diagnosis, the market is categorized into imaging, spinal fluid tests, brain biopsy, and others. The imaging segment is sub-segmented into electroencephalogram (EEG), magnetic resonance imaging (MRI), computerized tomography (CT), and others. On the basis of the treatment, the market is segmented into opiate drugs, clonazepam, sodium valproate, and others. On the basis of the end users, the market is segmented into hospitals & clinics, research organizations, diagnostic centers, medical research institutes, and others.
Research Methodology
Sources: National Institute of Neurological Disorders and Stroke, United States Census Bureau, Age UK, Indian Brand Equity Foundation, annual reports, press release, white paper, and company presentation
Regional Analysis
The Americas dominate the global market for Creutzfeldt-Jakob disease (CJD) market due to a huge patient population, presence of a well-developed healthcare sector, and market key players like Mylan N.V., GENERAL ELECTRIC, Apotex Inc., and others within the region. Moreover, changing lifestyle and growing healthcare expenditure fuels the market within the regional boundaries of the Americas.
Europe is second in the Creutzfeldt-Jakob disease (CJD) market owing to the availability of funds for research and development and growing geriatric population. In 2018, according to the Age UK, there are approximately 11.8 million people aged 65 or above within U.K. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe leads the market due to the presence of developed economies like Italy, U.K, France, and others.
Asia Pacific is estimated to be the fastest growing region for the Creutzfeldt-Jakob disease (CJD) market. This can be attributed due to the increasing geriatric population and a continuously developing healthcare sector within the region. According to the Indian Brand Equity Foundation in 2016, the Indian healthcare sector was projected to be one of the fastest growing industries. The healthcare sector in India is expected to grow at a CAGR of 22.87% from 2015 to 2020, reaching USD 280 billion by 2020.
On the other hand, the Middle East & Africa holds the least share in the Creutzfeldt-Jakob disease (CJD) market due to the presence of poor economies, and stringent government policies, especially within the African region. A majority of the Middle East & African region is estimated to be held by the Middle East due to the presence of developed economies like Kuwait, Qatar, Dubai, and others.
Key players
Some of the key players for the Creutzfeldt-Jakob disease (CJD) market are Teva Pharmaceutical Industries Ltd. (Israel), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Sandoz International GmbH (Germany), Sun Pharmaceutical Industries Ltd. (India), Apotex Inc. (Canada), Par Pharmaceutical. (U.S.), GENERAL ELECTRIC (U.S.), Koninklijke Philips N.V. (The Netherlands), Medtronic (U.S.), Siemens AG (Germany), Accuray Incorporated (U.S.), and others.
Frequently Asked Questions (FAQ) :
Creutzfeldt-Jakob disease or CJD is a rare, degenerative brain disorder which may lead to dementia and sudden death.
Global Creutzfeldt-Jakob disease market is expected to exhibit a strong 17.5% CAGR over the forecast period till 2027.
The growing geriatric population is the major driver for the Creutzfeldt-Jakob disease market.
The Americas dominate the global Creutzfeldt-Jakob disease market.
Leading players in the Creutzfeldt-Jakob disease market include Teva Pharmaceutical Industries, Mylan NV, and General Electric, among others.
